New tool to better inform patients about clinical trials

WIRB-Copernicus Group, provider of solutions to measurably improve the quality and efficiency of clinical research has acquired Patient Genesis’ ConsentNow eConsent technology

ConsentNow enables healthcare, pharmaceutical and medical device companies to share important information with patients during the informed consent process in a format that is both easy-to-use and easy-to-understand, helping to improve the informed consent process.

The technology employs custom video and animation segments to educate patients and online knowledge assessment questions to determine their level of understanding. This multimedia experience is delivered directly to the patient using a tablet device at the clinical site. 

Donald A. Deieso, Chairman and CEO at WIRB-Copernicus Group (WCG), said: “Knowledge empowers patients to make the best decisions for themselves and for their families. Using a patient-friendly format that includes plain language, videos and animation, ConsentNow helps to ensure that patients truly understand the benefits and risks of their clinical trial participation.”

ConsentNow is the newest addition to WCG’s interrelated platform of technology enabled services that measurably improve clinical trial efficiency while ensuring the safety of clinical trial participants.

Jeffrey S. Litwin, CEO of WCG’s MedAvante ProPhase, said: “In global clinical trials, communication can often pose significant challenges. ConsentNow enables providers to deliver important information in the patient’s native language and capture their feedback via questionnaire. This helps to eliminate confusion for the patient, and increase efficiency for the trial’s sponsor.”

Dr Litwin co-developed ConsentNow with Kevin B. Kimmel and their team at Patient Genesis, LLC in 2015.

In addition to improving the quality of patient education and the consistency of trial communications, ConsentNow fosters regulatory compliance because it is always loaded with the latest version of the protocol and will not allow the consent process to be completed until all required signatures are in place.

Another benefit of the ConsentNow solution is increased patient retention, as patients who are better informed at the start of the trial are less likely to drop out. With a secure, web-based dashboard, it provides both the sponsor and clinical site team members with real-time access to valuable site statistics.

Companies